Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Candel Therapeutics's operating margin for the twelve months ending Dec 31, 2022 was -27777.6%. For fiscal 2022 it was -27777.6%, against -20580.8% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -27777.6% | −7196.8 |
| FY2021 | Dec 31, 2021 | -20580.8% | −9532.8 |
| FY2020 | Dec 31, 2020 | -11048.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -26132.3% | −1164.5 |
| Q3 FY2022 | Sep 30, 2022 | -28648.4% | −2748.4 |
| Q2 FY2022 | Jun 30, 2022 | -28235.5% | −11135.5 |
| Q1 FY2022 | Mar 31, 2022 | -28987.1% | −13964.5 |
| Q4 FY2021 | Dec 31, 2021 | -24967.7% | −5209.7 |
| Q3 FY2021 | Sep 30, 2021 | -25900.0% | −17032.3 |
| Q2 FY2021 | Jun 30, 2021 | -17100.0% | −8651.6 |
| Q1 FY2021 | Mar 31, 2021 | -15022.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -19758.1% | – |
| Q3 FY2020 | Sep 30, 2020 | -8867.7% | – |
| Q2 FY2020 | Jun 30, 2020 | -8448.4% | – |
See a number that looks wrong?